Literature DB >> 3350974

Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.

J Y Borg1, M C Owen, C Soria, J Soria, J Caen, R W Carrell.   

Abstract

Antithrombin Rouen-II, a new inherited variant of antithrombin-III, was found in two members of a family with no definite history of thrombosis. The subjects had normal antigenic concentrations of antithrombin and normal progressive inhibitory activity. However, the variant had defective heparin and heparan sulfate cofactor activities, and was not activated by a synthetic pentasaccharide representing the minimum heparin sequence. The abnormal antithrombin was isolated using heparin-Sepharose chromatography, and on electrophoresis at pH 8.6 migrated more anodally than normal. Two-dimensional peptide mapping of tryptic and Staphylococcus aureus V8 protease digests was performed and the abnormal peptide was located by tryptophan staining. Amino acid sequence studies demonstrated a substitution of arginine at residue 47 by a serine. Evidence strongly suggests that arginine 47 is a prime heparin binding site in antithrombin and that it forms part of a proposed positively charged linear site (to which heparin binds) that stretches across the surface of the molecule from the A to the D helix.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3350974      PMCID: PMC329661          DOI: 10.1172/JCI113447

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Recurrent mutations in haemophilia A give evidence for CpG mutation hotspots.

Authors:  H Youssoufian; H H Kazazian; D G Phillips; S Aronis; G Tsiftis; V A Brown; S E Antonarakis
Journal:  Nature       Date:  1986 Nov 27-Dec 3       Impact factor: 49.962

2.  Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity.

Authors:  J Y Chang; T H Tran
Journal:  J Biol Chem       Date:  1986-01-25       Impact factor: 5.157

3.  Pyridoxylation of essential lysines in the heparin-binding site of antithrombin III.

Authors:  J M Pecon; M N Blackburn
Journal:  J Biol Chem       Date:  1984-01-25       Impact factor: 5.157

4.  Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells.

Authors:  J A Marcum; R D Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1985-01-16       Impact factor: 3.575

5.  A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville.

Authors:  M Aiach; M Nora; J N Fiessinger; M Roncato; D François; M A Gelas
Journal:  Thromb Res       Date:  1985-09-01       Impact factor: 3.944

6.  Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability.

Authors:  T Koide; S Odani; K Takahashi; T Ono; N Sakuragawa
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

7.  Antithrombin-III Denver, a reactive site variant.

Authors:  A W Stephens; B S Thalley; C H Hirs
Journal:  J Biol Chem       Date:  1987-01-25       Impact factor: 5.157

8.  Homozygous variant of antithrombin III: AT III Fontainebleau.

Authors:  C Boyer; M Wolf; J Vedrenne; D Meyer; M J Larrieu
Journal:  Thromb Haemost       Date:  1986-08-20       Impact factor: 5.249

9.  Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function.

Authors:  H Loebermann; R Tokuoka; J Deisenhofer; R Huber
Journal:  J Mol Biol       Date:  1984-08-15       Impact factor: 5.469

10.  Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan.

Authors:  J A Marcum; D H Atha; L M Fritze; P Nawroth; D Stern; R D Rosenberg
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157

View more
  4 in total

1.  Pleiotropic effects of antithrombin strand 1C substitution mutations.

Authors:  D A Lane; R J Olds; J Conard; M Boisclair; S C Bock; M Hultin; U Abildgaard; H Ireland; E Thompson; G Sas
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

2.  The anticoagulant activation of antithrombin by heparin.

Authors:  L Jin; J P Abrahams; R Skinner; M Petitou; R N Pike; R W Carrell
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

Review 3.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

4.  Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutation.

Authors:  P Molho-Sabatier; M Aiach; I Gaillard; J N Fiessinger; A M Fischer; G Chadeuf; E Clauser
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.